SciELO - Scientific Electronic Library Online

 
vol.132 número3Estudio de imágenes PET con Flúor18-Desoxiglucosa (F18FDG) en evaluación de elevación de marcador tumoral CA 19-9 en paciente con cistoadenocarcinoma mucinoso de páncreasTrombolisis intraarterial en trombosis de la arteria basilar: Recuperación de dos pacientes con síndrome de enclaustramiento índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

ISA P, Rodrigo; CASTRO G, Pablo  y  MARTINEZ S, Alejandro. Aerosolized iloprost combined with a phosphodiesterase inhibitor in the treatment of primary pulmonary hypertension. Rev. méd. Chile [online]. 2004, vol.132, n.3, pp.353-356. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872004000300011.

Iloprost, a prostacyclin analogue administered by inhalation, improves hemodynamic and functional class variables in patients with primary pulmonary hypertension. However, repetitive inhalations are required due to its short term effects. One potential approach to prolong and increase the effects of aerosolized iloprost might be to combine its use with phosphodiesterase inhibitors. We report a 36 years old female patient with primary pulmonary hypertension treated with this combination. After 18 months of therapy the patient had an improvement in functional class and in the 6 min walk distance despite persistence of high pulmonary pressures. Our case is in agreement with the reported beneficial effect of the association of sildenafil and iloprost. We postulate that functional improvement in primary pulmonary hypertension is not always related to a decrease in pulmonary artery pressure (Rev Méd Chile 2004; 132: 353-6).

Palabras clave : Iloprost; Phosphodiesterase inhibitors; Pulmonary heart disease; Sildenafil.

        · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons